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480Poly(amidoamine) Conjugates Containing
Doxorubicin Bound via an Acid-Sensitive
LinkerNathalie Lavignac,* Johanna L. Nicholls, Paolo Ferruti, Ruth DuncanPoly(amidoamine)s with amino pendant groups were prepared by hydrogen-transfer poly-
addition of primary and secondary amines to bis-acrylamines. Dansyl cadaverine (DC)
doxorubicin (Dox) were bound to the polymers via a cis-aconityl spacer to give conjugates
containing 3 mg of DC per mg of polymer and
28 to 35 mg of Dox per mg of polymer. Release
of DC and Dox at physiological and acidic pH
varied from 0 to 35% over 48 h and was pH
dependent. Although the ISA1Dox conjugate
(IC50¼ 6 mg Dox mL1) presented similar
toxicity as the parent polymer without Dox,
ISA23Dox showed increased toxicity (IC50¼ 10
mg Dox mL1). These results suggest that
ISA23Dox is able to release biologically active
Dox in vitro and that this conjugate might be
suitable for further development.Introduction
Following i.v. administration, low-molecular-weight drugs
distribute into almost all tissues and intracellular com-
partments due to passive diffusion or active transport
through cell membranes.[1] For anticancer agents such as
anthracyclines this results in non-specific toxicity. WhenN. Lavignac, J. L. Nicholls, R. Duncan
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the drug is modified at the body and cellular level and
passive targeting to tumour site is obtained via the
enhanced permeation and retention (EPR) effect.[2–4]
Several macromolecular systems have been described to
deliver doxorubicin (Dox)[5,6] including N-(2-hydroxypro-
pyl)methacrylamide (HPMA) copolymers[7,8] and poly
(ethylene glycol) (PEG) conjugates.[9,10] Here, we described
newpolymer-Dox conjugates based on poly(amidoamine)s
(PAAs).[11–12] PAAs are water-soluble polymers and are
>100-fold less toxic [13,14] than other polycationic vec-
tors.[15–17] Poly(amidoamine)s also present the advantage
to degrade to oligomeric products in aqueousmediawithin
days or weeks, depending on their structures.[18,19] Owing
to their capacity to undergo a conformational change from
a coiled structure at pH¼ 7.4 to amore extended onewhen
exposed to acidic pH,[20–22] most recent effort have been
directed to develop stimuli-responsive constructs for
biomacromolecules intracellular delivery.[23–26] However,DOI: 10.1002/mabi.200800163
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carrier. Poly(amidoamine)s with hydroxy pendant groups
have been used to develop PAA/mitomycin (MMC)
adducts[12,27] whereas PAAs containing b-cyclodextrin
were used to deliver platinate (Pt) [28] and acyclovir.[29]
Poly(amidoamine)/MMC conjugates were found to be less
toxic than free MMC. When given by i.p. route, they were
equi-active compare to MMC resulting in long-term
survival of DBA2 mice bearing L1210 tumour cells and
treated with the conjugate.[12] Similarly PAA/Pt were equi-
active compare to cisplatin in an i.p. L1210 leukaemia
model [28] and in vitro, PAA/acyclovir complexes exhibited
a higher antiviral activity against herpes simplex viruses
compare to the free drug.[29]
As Dox is inactive in its conjugated form,[8] tumour cell-
specific released of the drug and subsequent biological
activity must be achieved by the choice of a suitable
degradable linker between the polymer and the drug. By
taking advantage of the pH-gradient between the extra-
cellular matrice and the endosome it could be possible to
use a pH-sensitive spacer that would be stable at
physiological pH whereas it would degrade in the acidic
vesicles allowing the release of the drug in the cytosol.[30,31]
Poly(amidoamine)-drug conjugates (Dox or dansyl cada-
verin)were synthesised using a cis-aconityl linker. Stability
of the conjugateswas evaluated in solution at pH¼ 7.4 and
5. An in vitro cytotoxicity of Dox-based polymers was
assessed using mouse melanoma B16F10 cells.Experimental Part
Materials
Cis-aconitic anhydride and dansyl cadaverine (DC)were purchased
from Fluka (Buchs, Germany).N-hydroxy-sulfosuccinamide (sulfo-
NHS) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC)
were purchased from Pierce (Cramlington, UK). Triethylamine
(TEA), sodium hydroxide (NaOH), Sephadex G25, gelonin, 5-
dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide (MTT) and
Triton X-100 were all from Sigma (Dorset, UK). Dichloromethane,
methanol and dialysing membrane were from Fisher (Loughbor-
ough, UK). The PD10 columns were from Pharmacia and PBS was
supplied from Oxoid Ltd. (Basingstoke, UK). RPMI 1640 medium
(25 103 MHEPES) supplementedwith L-glutamine, foetal bovine
serum (FBS) were purchased from Gibco-BRL (Paisley, UK). The
B16F10 mouse melanoma cells were from ATCC (CRL-6475).Scheme 1. Synthesis of ISA1DC conjugate.Synthesis of PAAs Conjugates
Synthesis of PAAs with Amino-Pendant
Group
The PAAs with amino-pendant group
(ISA1NH2 and ISA23NH2) were synthesised
as described elsewhere.[32] The content of side
chains terminated amino groups was deter-Macromol. Biosci. 2009, 9, 480–487
 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimmined using a ninhydrin assay.[33] Samples and 3-amino-1-
propanol standards were prepared in water and 200 mL aliquots
were added to Eppendorfs. After addition of 200 mL of ninhydrin
reagent, solutions were incubated at 100 8C for 10 min. 300 mL of
50 vol.-% ethanol was then added after cooling on ice for 2 min.
Absorbance was measured at 570 nm within 10 min. Unmodified
PAAs, used as control, did not give false positive results.
Synthesis of ISA1-Dansyl Cadaverine
ISA1-dansyl cadaverine conjugate was synthesised as described in
Scheme 1. Briefly, ISA1NH2 (50 mg) was dissolved in 5 mL of PBS
(0.1 M, pH¼8). The pH was adjusted back to 8 using 1 M NaOH.
50 mg of cis-aconitic anhydride (320 mmol) were added slowly
whilst continually checking the pH and maintaining it between 8
and 8.5 using 1 M NaOH. The solution was left to react for 1 h at
room temperature. The product was purified by gel permeation
chromatography (GPC) on a Sephadex G25 column using PBS as
eluent (0.1 M, pH¼ 7.4). Fractions containing the polymer were
detected at 280 nm, pooled together and dialysed overnight
against water (2 000 Da MW cut-off membrane). The final product
was lyophilised. Conjugation of DC to the polymer derivative was
carried out using a modified protocol adapted from Al-Shamkhani
and Duncan.[34] ISA1-cis-aconityl (30 mg) was dissolved in 1.9 mL
carbonate buffer (0.1 M, pH¼ 9). 1-Ethyl-3-(3-dimethylaminopro-
pyl) carbodiimide (0.78 mg, 4.1 mmol) was added. The solution
was stirred for 2 min. at room temperature and sulfo-NHS
(0.82mg, 3.8 mmol) was added. The pH was adjusted to pH¼ 9
using NaOH (1.0 M). The solution was stirred at room temperature
for 1 h after which DC (1.2 mg, 3.6 mmol) was added and the
mixture stirred in the dark for a further 1.5 h. The conjugate was
purified by GPC. Fractions containing the conjugate were detected
by fluorescence at 520 nm (excitation wavelength at 300 nm). The
fractions were pooled and lyophilised. The recovered product was
desalted using a PD10 column and lyophilised.
Synthesis of PAA-Dox
Poly(amidoamine)-Dox was synthesised as described in Scheme 2.
Doxorubicin-cis-aconityl was prepared using the method of Shen
and Ryser with somemodifications.[35] Doxorubicin hydrochloride
(50 mg, 86.2 mmol) was dissolved in 15 mL of ice-cold carbonate
buffer (0.1 M, pH¼ 9). Cis-aconitic anhydride (50 mg, 0.32 mmol)
was added slowly at 0 8C while maintaining a pH of 8.5 by
addition of ice-cold NaOH (0.5 M). The reactionmixture was stirred
at 0 8C for 20 min. and then at room temperature (20 min.). The
reaction was cooled on ice and acidified with ice-cold HCl (1 M) till
precipitation. The precipitate formed was isolated by centrifuga-
tion (10 min at 4 000 g and 4 8C), dissolved in doubled distilled
water and recovered by lyophilisation. Conjugation of Dox-cis-
aconityl to PAA was carried out as previously described.[36]
Doxorubicin-cis-aconityl (7mg, 10mmol)was dissolved in 12mL ofwww.mbs-journal.de 481
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Scheme 2. Synthesis of ISA23Dox and ISA1Dox conjugates.
482PBS (0.1 M, pH¼7.4). 1-Ethyl-3-(3-dimethylaminopropyl) carbo-
diimide (20 mg, 0.1 mmol) was added. The solution was stirred for
2min at room temperature and sulfo-NHS (25mg, 0.12mmol) was
added. The pH was adjusted to pH¼9 using NaOH (1.0 M). The
solution was stirred at room temperature for 30 min. after which
ISA1-NH2 or ISA23-NH2 (100 mg) was added. pH was adjusted to
neutral with NaOH (1 M) and the mixture stirred for 20 h in the
dark. The conjugate was purified by GPC. Fractions containing the
polymer were pooled and lyophilised. The recovered product was
desalted using a PD10 column and relyophilised.
Characterisation of PAAs Conjugates
Determination of Doxorubicin or Dansyl Cadaverine
Content
Dansyl cadaverine and Dox content in the conjugates were
estimated by UV spectrophotometry at 485 (Dox) and 335 nm (DC)
using free DC or free Dox as standards.[37]
Determination of Free Doxorubicin or Free Dansyl
Cadaverine
The amount of free drug in the conjugates was determined by
reverse-phase HPLC after extraction in organic solvent.[38] Briefly,
100 mL of ammonium formate (1 M, pH¼8.5) was added to the
conjugates (0–5 mg) dissolved in water (900 mL). For Dox
containing samples, daunomycin (500 ng) was used as internal
standard. After addition of 5 mL of chloroform, the samples were
mixed and centrifuged for 10 min. at 13 000 rpm. The aqueous
phase was discarded, the solvent evaporated under nitrogen and
the residues re-dissolved in methanol (100 mL). Recovered-free DC
and Dox were quantified by HPLC using aWaters Spherisorb 5 mm
ODS2 column (1503.9 mm2). For DC, the mobile phase (H2O/
methanol/TEA, 70:28:2 by volume) was delivered at a flow rate of
1 mL min1 with a Jasco PU-980 Intelligent HPLC pump. DC
fluorescence was detected at 508 nm with an excitation
wavelength at 336 nm using a GBC LC1255 Fluoro detector. For
Dox, themobile phasewas propanol/H2O, 29:71 vol.-%, the pHwas
adjusted to 3.5 with orthophosphoric acid. Dox fluorescence was
detected at 560 nm with an excitation wavelength at 480 nm.
Release Study of DC or Dox from Conjugates at
Different pH
Stability of the cis-aconytil linker was evaluated in buffer
solutions at several pH. ISA1DC (7 mg mL1, 21.77 mg ofMacromol. Biosci. 2009, 9, 480–487
 2009 WILEY-VCH Verlag GmbH & Co. KGaA, WeinheimDC per mL), ISA1Dox (4 mg mL1, 357.5 mg of Dox per mL) and
ISA1Dox (4 mg mL1, 281.7 mg of Dox per mL) were dissolved in
citrate/phosphate buffers 0.1 M at pH¼ 5 and 7.4. The solutions
were incubated in a water bath at 37 8C. Aliquots (100 mL) were
removed at different time points, immediately frozen with liquid
nitrogen and stored into a freezer (80 8C) until further analysis.
Free DC and Dox were extracted and quantified by HPLC as
described before.Evaluation of in vitro Cytotoxicity of Doxorubicin
Conjugates
The cytotoxicity of the PAADox conjugates was assessed using a
murine melanoma B16F10 model. Cells were cultured in RPMI-
1640 supplemented with 5103 M L-glutamine 10 vol.-% heat-
inactivated FBS and maintained at 37 8C in a humid incubator
with a 5% CO2 atmosphere. No antibiotics were added. Polymer
cytotoxicity was assessed during the log phase of cell growth
using anMTT assay as described previously.[25] Cellswere added to
96-well microtitre plates at a density of 1 104 cells well1 24 h
prior to the assay. Polymer solutions (0.2 mm filtered) were made
in complete RPMI-1640medium to give a concentration range of 0
to 4 mg of polymer per mL. At the start of the experiment the
culture medium was removed and the desired polymer solution
was added (100 mL). After 67 h, MTT (20 mL; 5 mg mL1 in PBS
sterile filtered) was added to eachwell and the plates re-incubated
for a further 5 h. The formazan crystals were dissolved in DMSO
and concentration read at 550 nm using a microtitre plate reader.
The results were expressed as per cent viability relative to a
control containing no polymer (i.e. cells grown in media alone
were used as a reference for 100% viability).Results and Discussion
The concept of polymer drug carrier is not new; Ringsdorf
proposed it 30 years ago.[39] He described his model as a
water-soluble macromolecular prodrugs consisting of an
inert carrier to which the drug is attached directly or via a
degradable spacer. A targeting moiety can be additionally
added for cell-specific delivery via receptor-mediated
endocytosis. Over the year, several systems using passive
or enzymatic hydrolysis as well as pH controlled releaseDOI: 10.1002/mabi.200800163
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ISA1 39 200 1.72 – –
ISA23 38 800 1.75 – –
ISA1NH2 16, 700 1.70 4.5 –
ISA23NH2 22, 700 1.98 4 –
ISA1DC 16, 100 1.84 – 0.3
ISA1Dox 17, 800 1.87 – 3.6
ISA23Dox 23, 500 2.31 – 2.8
a)Mw and PDI (polydispersity index) were determined by GPC
using poly(N-vinylpyrrolidone) standards; b)Content of pendant
amino groups; c)DC or Dox.and reduction sensitive spacers were developed.[31]
Proteolytically degradable bonds are generally used for
lysosomotropic drug delivery and peptidyl linkers, such as
Gly-Phe-Leu-Gly which is degraded by lysosomal enzymes
such as cathepsin B, are amongst the most widely used
spacers.[30] However, for cells with limited content of
lysosomes, this might preclude the therapeutic effect of
such macromolecular prodrugs.[40] Furthermore, recent
results suggest that the in vivo enzymatic degradation of
this type of linker relying on cathepsin B might be gender
dependant.[41] N-(2-hydroxypropyl)methacrylamide-Dox
conjugates prepared with pH sensitive spacers, hydrazone
bond[42] and cis-aconityl[43] were found to be more
cytotoxic than PK1 (an HPMA-dox conjugate using a
pedtidyl linker) probably due to a higher release rate of the
drug. Polymer conjugates using a pH sensitive linker could
therefore present some advantages. In this paper, we
report the synthesis and preliminary evaluation of
PAAs-based conjugates containing either DC or Dox linked
to the polymer backbone via a cis-aconityl linker. DC was
initially chosen as a model molecule. It was later replaced
by Dox due to its potential therapeutic application in
chemotherapy.
Poly(amidoamine)s containing amino groups in their
side chains (Figure 1) were synthesised by hydrogen
transfer polyaddition of aliphatic amines to bisacryla-
mides.[32] The molecular weight (Mw) of ISA23NH2
and ISA1NH2 were 22.7 and 16.7 kDa, respectively; their
polydispersity indiceswere 1.9 and 1.7 (Table 1). The amine
function was introduced using 1-triphenylmethylamino-
2-aminoethane (TPHMAE) as comonomer (5 mol-% theo-
retically). The content of incorporated TPHMAE was
estimated using a ninhydrin assay as described in the
methods. ISA23NH2 and ISA1NH2 contained 4 and
4.5mol-% of amino groups, respectively. Synthesis of the
conjugates was carried out using sequential procedures as
described in Scheme 1 and 2. DC-based polymer was
synthesised via a polymer precursor obtained by the
reaction of cis-aconitic anhydridewith the amine groups of
ISA1NH2 (Scheme 1). Dansyl cadaverine was conjugated toFigure 1. Structure of the PAAs.
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EDC and sulfo-NHS. Unreacted DC was removed by
Sephadex G25 column chromatography and the resulting
conjugate was desalted using a PD10 column (Figure 2).
Dox-based polymers were prepared using a similar
procedure (Scheme 2), respective polymers were reacted
with N-cis-aconityl Dox, prepared by acylation of the
amino group of Dox-HCl.[35] Drug loading determined
spectrophotometrically was 3.11 mg of DC per mg of
polymer for ISA1DC conjugate, 35.72 mg of Dox per mg of
polymer for ISA1-cis-Dox conjugate and 28.17 mg of Dox
per mg of polymer for ISA23Dox conjugate. No detectable
drug (less than 0.1 wt.-% free drug relative to total DC or
Dox) was found in conjugates after purification.
Doxorubicin is inactive in its conjugated form and to
exert its biological activity it has to be released from the
polymer backbone.[8] However, after i.v. injection, the
conjugate must be stable while in the blood stream and to
avoid unspecific cytotoxicity releasemust only occur in the
acidic compartments of the tumour cells. Stability of thepH sensitive linker was though exam-
ined at 37 8C in citrate/phosphate buf-
fers at pH values of 5 and 7.4 to mimic
endosomes and extracellular pHs
(Figure 3 and 4). The amount of drug
released from the PAAs conjugates was
quantified by HPLC. As expected the
release profiles depended on the pH. For
all conjugates the amount of drug
released was lower at pH¼ 7.4 with
less than 3% of drug released within
42h. At acidic pH, hydrolysis of the cis-
aconityl spacer occurred slowly in all
cases, although the release rates werewww.mbs-journal.de 483
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Figure 2. Purification of the conjugate ISA1DC by GPC on a Sepha-
dex G25 column using PBS as eluent (0.1 M, pH¼ 7.4). Inset: elution
profile after desalting on the PD10 column.
484different for each conjugate. For ISA1DC polymer (Figure 3)
the release started after a time lag of 6 h whereas for Dox-
based conjugates degradation of the cis-aconityl linker had
already occurred after 2 h of incubation. For ISA23Dox
(Figure 4b) the release increased regularly over the period
of incubation with 30% of Dox released after 42 h. For ISA1,
the release profile was different (Figure 4a). Nearly 10% of
Dox was released within 2 h compare to less than 4% for
ISA23. After 24 h of incubation, the release of Dox wasFigure 3. Release study of DC from ISA1DC. Stability of the cis
aconityl linker at 37 8C, was studied at pH¼ 5 () and
pH¼ 7.4 (~). (Data represents mean SEM; n¼6).
Figure 4. Release study of Dox from (a) ISA1Dox and (b) ISA23Dox.
Stability of the cis-aconityl linker at 37 8C, was investigated at
pH¼ 5 () and pH¼ 7.4 (~) (Data representsmean SEM; n¼6).
Macromol. Biosci. 2009, 9, 480–487
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reached a plateau at approximately 20%.
Shen and Ryser[35] were the first to describe the
synthesis of poly(D-lysine)-daunomycin (DNM) conjugates
using a cis-aconytil spacer. Similarly, they found that the
linker was more stable at pH¼ 6 than at pH¼ 4 with a
half-life ofmore than 96 h in the first case and less than 3 h
in the second. Further in vitro studies, demonstrated the
release of DNM in the endosome compartment. To
evaluate the release of Dox in vitro, the cytotoxicity of
the PAA-cis-Dox conjugates synthesised was assessedDOI: 10.1002/mabi.200800163
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Figure 5. Cytotoxicity of PAADox relative to free Dox. Viability is
expressed as per cent of the growth of control B16F10 mouse
melanoma cells incubated in medium alone. IC50: Dox concen-
tration at which 50% of the cells are dead. ISA23Dox (~), ISA1Dox
(&) and Free Dox () (data represents mean SEM; n¼6).
Figure 6. Cytotoxicity of PAAss toward B16F10 mouse melanoma.
Viability is expressed as per cent of the growth of control cells
incubated in medium alone. Panel (a) ISA1 (&), ISA1NH2 () and
ISA1Dox (~). Panel (b) ISA23 (&), ISA23NH2 () and ISA23Dox (~)
(data represents mean SEM; n¼6).using a murine melanoma B16F10 model and an MTT
assay. Free Dox and parent polymers ISA1, ISA1NH2,
ISA23 and ISA23NH2 were used as control. Cytotoxicity
of both conjugates (IC50¼ 6 mg Dox mL1 for ISA1Dox
and IC50¼ 10 mg Dox mL1 for ISA23Dox) was lower
compare to free Dox (IC50¼ 0.3 mg Dox mL1) (Figure 5).
This has been reported before for other polymer-Dox
conjugates.[10] It is due to low rate of endocytic uptake and
endosomotropic/lysosomotropic activation as the limiting
rate for the conjugate compare to the free drug that can
diffuse through cell’s membrane. For conjugate ISA1Dox
the toxicity was similar to that of the parent polymers
(IC50¼ 1.5 mg polymer mL1) (Figure 6a). Therefore the
toxicity could not be correlated with the release of Dox. For
conjugate ISA23Dox, cell death was dose dependent
(Figure 6b) and cell death increased compare to the parent
polymers that were not toxic (ISA23; ISA23NH2) under the
same conditions. These results confirmed the release of the
drug from the polymer backbone (i.e. ISA23Dox) after
degradation of the cis-aconityl linker in the endosomal/
lysosomal compartments.
Our results suggest that the mechanism of Dox release
from the polymer backbone (ISA23 or ISA1) is different
(Figure 4) and that the conjugates present different
biological activity (Figure 6). It has been showed that
when daunomycin is acylated with cis-aconitic anhydride
two isomers are obtained (cis-DNM and trans-DNM).[44]
Recently, Kakinoki et al.[45] reported similar results for
Dox. They conjugated Dox to poly(vinyl alcohol) (PVA) via a
cis-aconityl linker. They found that in solution, the
configuration of the intermediate isomers (cis-Dox andMacromol. Biosci. 2009, 9, 480–487
 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimtrans-Dox) had an influence on the kinetics release profile
of Dox from the polymer. At pH¼ 5 the half-life for the
release of Dox was 3 h for PVA-cis-Dox whereas it was 14 h
for PVA-trans-Dox. They concluded that the cis conforma-
tion catalysed the hydrolysis of the amide bond. They also
demonstrated that the biological activity of the polymer
conjugate (PVADox) depended on the configuration of the
aconityl-Dox isomer. Under similar conditions the cis-Dox
conjugate displayed higher toxicity. In the present study,
we did not isolate the isomers (cis-Dox and trans-Dox).www.mbs-journal.de 485
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486The proportion of cis-Dox and trans-Doxmight therefore be
different between the two conjugates, which could
potentially explain the difference between their release
profile and activity.
ISA1 and ISA23 are poly(amidoamine)s with different
chemical structure. This could also alter the biological
activity of the Dox conjugates. Several studies have shown
that the structure of polymers can have an effect on their
cellular uptake and that polymers with different archi-
tecture may have different intracellular trafficking.[46,47]
Our conjugates are stimuli responsive. The release of Dox is
pH dependent and requires substantial access to the acidic
compartment of the cells. It has already been suggested in
a previous study that the intracellular fate of ISA1 and
ISA23 polymers may be different.[24] Such variation in
trafficking may affect the kinetics of Dox release in vitro
and could also explain the difference of activity between
ISA1Dox and ISA23Dox. Two HPMA conjugates (PK1 and
PK2) with similar chemical structure displayed different
maximum-tolerated dose (MTD) in clinical trials. A recent
study using small angle neutron scattering (SANS)
suggested that this difference might be explained by
different conjugates conformation.[48] Such experiments
have already shown the pH-dependent changes in
conformation of poly(amidoamine)s,[20–22] experiments
with the present conjugates could lead to further insight
into the mechanism of Dox release.Conclusion
Poly(amidoamine)s/Dox conjugates (ISA1Dox and ISA23-
Dox) were synthesised from PAAs with amino pendant
groups and Dox acylated with cis-aconitic anhydride.
Although both conjugates demonstrated pH-dependent
stability in buffer solutions, only ISA23Dox showed the
ability to release biologically active Dox in the endosomal
compartment of B16F10 cells. Influence of the Dox isomer’s
configuration (cis-Dox or trans-Dox) is currently under
investigation. Macromolecular systems are quite often
eliminated from the blood circulation by the reticulo-
endothelial system. However, ISA23 is known to possess
enhanced blood circulation and in vivo experiments using
animalmodels have shown it does accumulate in tumours.
It would be though also interesting to undertake
pharmacokinetic studies to see if the ISA23Dox conjugate
accumulates in tumours and to evaluate the fate of the
remaining drug bearing polymer.Acknowledgements: We thank BBSRC for supporting this work.
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